Stromal-induced epithelial-mesenchymal transition induces targetable drug resistance in acute lymphoblastic leukemia

Summary: The bone marrow microenvironment (BME) drives drug resistance in acute lymphoblastic leukemia (ALL) through leukemic cell interactions with bone marrow (BM) niches, but the underlying mechanisms remain unclear. Here, we show that the interaction between ALL and mesenchymal stem cells (MSCs)...

Full description

Bibliographic Details
Main Authors: Chun Shik Park, Hiroki Yoshihara, Qingsong Gao, Chunxu Qu, Ilaria Iacobucci, Pankaj S. Ghate, Jon P. Connelly, Shondra M. Pruett-Miller, Ben Wagner, Camenzind G. Robinson, Ashutosh Mishra, Junmin Peng, Lei Yang, Zoran Rankovic, David Finkelstein, Selina Luger, Mark Litzow, Elisabeth M. Paietta, Nikhil Hebbar, M. Paulina Velasquez, Charles G. Mullighan
Format: Article
Language:English
Published: Elsevier 2023-07-01
Series:Cell Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S221112472300815X
Description
Summary:Summary: The bone marrow microenvironment (BME) drives drug resistance in acute lymphoblastic leukemia (ALL) through leukemic cell interactions with bone marrow (BM) niches, but the underlying mechanisms remain unclear. Here, we show that the interaction between ALL and mesenchymal stem cells (MSCs) through integrin β1 induces an epithelial-mesenchymal transition (EMT)-like program in MSC-adherent ALL cells, resulting in drug resistance and enhanced survival. Moreover, single-cell RNA sequencing analysis of ALL-MSC co-culture identifies a hybrid cluster of MSC-adherent ALL cells expressing both B-ALL and MSC signature genes, orchestrated by a WNT/β-catenin-mediated EMT-like program. Blockade of interaction between β-catenin and CREB binding protein impairs the survival and drug resistance of MSC-adherent ALL cells in vitro and results in a reduction in leukemic burden in vivo. Targeting of this WNT/β-catenin-mediated EMT-like program is a potential therapeutic approach to overcome cell extrinsically acquired drug resistance in ALL.
ISSN:2211-1247